CIPLA LTD. - 500087 - Dissolution Of Wholly Owned Step-Down Subsidiary
Dissolution of Cipla Dibcare (Pty) Limited i.e. wholly owned step-down subsidiary of the Company28-06-2024
28-06-2024
Cipla - Classification Of Goa Inspection Remains Key: Motilal Oswal
Comprehensive measures required to resolve regulatory issues27-06-2024
CIPLA LTD. - 500087 - Update On USFDA Inspection At Company'S Manufacturing Facility In Patalganga, Maharashtra, India
Update on USFDA inspection at Company''s manufacturing facility in Patalganga, Maharashtra, India25-06-2024
Cipla Hits Two-Week Low After FDA Flags Issues At Goa Facility
The stock declined as much as 3.02% during the day to Rs 1,495.05 apiece on the NSE.24-06-2024
CIPLA LTD. - 500087 - USFDA Inspection At Company'S Manufacturing Facility In Goa, India.
USFDA inspection at Company''s manufacturing facility in Goa, India21-06-2024
CIPLA LTD. - 500087 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for BlackRock Inc21-06-2024
Cipla, Sun Pharma ink non-exclusive agreement with Takeda on acid-reflux drug
Cipla and Sun Pharma will independently commercialise the drug in India under their respective trademark brands21-06-2024
CIPLA LTD. - 500087 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Please find enclosed the intimation for loss of share certificates19-06-2024
Cipla invests additional 3 mn euro in mRNA technology company Ethris
The aim is to accelerate Cipla's entry into the mRNA space and deliver innovative mRNA-based therapies, particularly targeting respiratory treatments, to patients in emerging markets18-06-2024
CIPLA LTD. - 500087 - Press Release- Cipla EU To Invest Additional EUR 3 Million In Ethris
Press Release- Cipla EU to invest additional EUR 3 million in Ethris18-06-2024